Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Florian Caiment: Innovator in Predicting Cardiotoxicity Risk
Introduction
Florian Caiment is a notable inventor based in Maastricht, Netherlands. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach utilizes a combination of circulating microRNAs as biomarkers for this critical health issue.
Latest Patents
Florian Caiment holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a specific set of 10 circulating miRNAs. These include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also encompasses a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs in patients.
Career Highlights
Throughout his career, Florian Caiment has worked with esteemed institutions such as the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. His work has been pivotal in advancing the understanding of cardiotoxicity in cancer treatment.
Collaborations
Florian has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. Their combined expertise has contributed to the success of his research and innovations.
Conclusion
Florian Caiment is a distinguished inventor whose work in predicting cardiotoxicity risk has the potential to significantly impact cancer treatment protocols. His innovative methods and collaborations highlight the importance of research in improving patient outcomes.